An antibiotic's anti-inflammatory power, not its antimicrobial one
In laboratories at two Brazilian universities, researchers have uncovered an unexpected kinship between inflammation and panic — finding that minocycline, a decades-old antibiotic, may quiet the body's alarm systems in ways that rival conventional anxiety medications. The study, small but carefully constructed, suggests that panic disorder is not purely a disorder of the mind or its neurotransmitters, but may carry within it a biological fire that anti-inflammatory agents can help extinguish. It is an early finding, not a cure, but it opens a corridor of inquiry that could gradually redirect how medicine approaches the suffering of those who live with panic.
- Forty-nine patients with panic disorder were exposed to carbon dioxide-induced suffocation sensations — a controlled provocation that mimics the terror of a real attack — and those given minocycline responded as well as those given clonazepam, the standard benzodiazepine treatment.
- The antibiotic's power came not from fighting bacteria but from suppressing pro-inflammatory cytokines like interleukin-2 and interleukin-6, while simultaneously boosting the anti-inflammatory signal of interleukin-10.
- Benzodiazepines like clonazepam remain effective but carry serious risks of dependence and side effects, creating urgent pressure to find alternatives that work through different biological pathways.
- The study is too small and too brief — just 49 participants over seven days — to justify clinical adoption, and researchers are calling for larger, longer trials before any conclusions harden into practice.
- The deeper disruption is conceptual: if inflammation drives panic, then psychiatry may need to look beyond neurotransmitters and toward anti-inflammatory medicine as a legitimate frontier for treating mental distress.
A team of researchers at two major Brazilian universities set out to test an unconventional idea: that minocycline, an antibiotic long used against bacterial infections, might have something to offer people who suffer from panic disorder. The results, published in Translational Psychiatry, suggest the idea is worth taking seriously.
The study enrolled 49 people diagnosed with panic disorder. After seven days on minocycline, participants were exposed to air enriched with 35 percent carbon dioxide — a method that reliably induces the physical sensations of a panic attack. A separate group received clonazepam, the benzodiazepine most commonly prescribed for anxiety. Minocycline performed comparably to the established drug.
The mechanism had nothing to do with fighting infection. Minocycline appeared to work by reducing pro-inflammatory cytokines — particularly interleukin-2 soluble receptor alpha and interleukin-6 — while raising levels of interleukin-10, a molecule that promotes anti-inflammatory responses. The implication is that inflammation may be a meaningful driver of panic disorder, not merely a bystander.
This matters because benzodiazepines, though effective, carry well-documented risks of dependence and adverse effects. A drug with a different mechanism and an already-established safety record could offer patients and physicians a genuine alternative. But the researchers are measured in their claims: the trial was small, the observation window short, and much remains to be understood about why inflammation and panic are linked at all.
What the study does accomplish is shift the horizon. If psychiatric conditions like panic disorder have an inflammatory dimension, then the search for new treatments need not be confined to drugs that act on neurotransmitters alone. Larger trials, longer timelines, and broader comparisons lie ahead — but a Brazilian research team has made the connection visible, and that visibility is itself a form of progress.
Researchers at two major Brazilian universities have found something unexpected in a common antibiotic: a possible tool for treating panic attacks. The discovery emerged from a small but carefully designed study that challenges how we think about what causes panic disorder and what might ease it.
The work involved 49 people diagnosed with panic disorder. At the start of the study and again after seven days of taking minocycline—an antibiotic typically used for bacterial infections—each participant breathed air mixed with 35 percent carbon dioxide. This creates the physical sensation of suffocation, mimicking the body's experience during a panic attack. A control group took clonazepam, a benzodiazepine commonly prescribed for anxiety. The results, published in the journal Translational Psychiatry, showed that minocycline produced effects comparable to the standard medication.
What made the difference was not the antibiotic's antimicrobial properties but its ability to dampen inflammation. Patients who took minocycline showed measurable drops in pro-inflammatory cytokines—signaling molecules that promote inflammation throughout the body. Specifically, levels of interleukin-2 soluble receptor alpha and interleukin-6 fell significantly. At the same time, levels of interleukin-10, which triggers an anti-inflammatory response, increased. The drug also reduced activity in other cytokines linked to various inflammatory processes.
This finding opens a door that researchers had not fully explored before. If inflammation plays a meaningful role in panic disorder, then anti-inflammatory medications might offer a new path forward—one that sidesteps the benzodiazepines that have long been the standard treatment. Those drugs work quickly and effectively but carry risks of dependence and side effects that concern both patients and doctors. An antibiotic already approved for other uses, with a different mechanism and a different safety profile, could potentially offer an alternative.
But the researchers are careful not to overstate what they have found. The study was small. Seven days is a short window. More work is needed before minocycline could be considered a legitimate treatment for panic disorder. What the research does do is point toward a larger possibility: that psychiatric conditions long treated as purely neurological or psychological problems may have an inflammatory component that responds to the right medication. That insight could reshape how researchers hunt for new treatments, shifting focus toward drugs with anti-inflammatory action rather than only those that affect neurotransmitters in the brain.
The next phase will require larger trials, longer observation periods, and careful comparison with existing treatments. But the door is open now. Other anti-inflammatory drugs may be worth testing. The question of why inflammation and panic are connected remains to be fully answered. What matters for now is that a team of Brazilian scientists has shown that the connection is real, and that it might be exploitable.
Notable Quotes
The study opens the path toward searching for other anti-inflammatory medications that could affect panic disorder treatment— Researchers (paraphrased from source)
The Hearth Conversation Another angle on the story
Why would an antibiotic help with panic attacks? That seems like it's treating the wrong problem.
That's the insight here—panic attacks might not be purely a neurological problem. The inflammation markers changed, which suggests the body's immune response was involved in the panic response itself.
So you're saying panic is partly an inflammatory disease?
The study suggests inflammation plays a role, at least in some people. Whether it's the root cause or a contributor—that's still unclear. But if it's part of the picture, then anti-inflammatory drugs become relevant.
Why not just use other anti-inflammatory drugs then? Why specifically an antibiotic?
Minocycline has anti-inflammatory properties beyond its antibiotic function. It's already approved and used safely. That makes it a practical place to start. But yes, the research opens the door to testing other anti-inflammatory agents too.
What's the advantage over clonazepam, which already works?
Clonazepam works fast but carries dependence risk and side effects. If minocycline works similarly without those risks, it's a meaningful alternative. But we don't know that yet—this was a seven-day study. Real treatment takes longer.